Making it in Manufacturing

ARTO Talent
  • 0.0 (0)
  • PROFESIONES
  • CADA SEMANA

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

  1. The Truth About Automation in Modern Biomanufacturing - Daniel Shearer, FujiFilm

    HACE 6 DÍAS

    The Truth About Automation in Modern Biomanufacturing - Daniel Shearer, FujiFilm

    95% of our viewers aren't following, please check! How do you bring a $400M biotech facility online… without getting automation wrong? This week, in another episode of Making It in Manufacturing, we feature Daniel Shearer, Head of Automation at FUJIFILM, with over 15+ years of experience spanning automation engineering, capital projects, and large-scale biotech manufacturing environments. In this episode, Dan covers: - The $400M multi-modal manufacturing asset at Fujifilm’s Billingham site and what it takes to bring it online - How automation has evolved over the past decade and why data integration is now critical - The importance of standardisation, and how it can reduce cost, validation time, and complexity - Integration challenges across systems like MES, LIMS, and quality platforms - The most common pitfalls in automation projects, and how to avoid them Whether you're building a new facility or scaling existing operations, this episode is packed with practical insights from someone working at the forefront of modern biomanufacturing. 👉 Be sure to check out the full episode and learn how to get automation right from day one. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/?viewAsMember=true Spotify: https://open.spotify.com/show/0kEcRZO... Instagram: https://www.instagram.com/arto.talent... TikTok: https://www.tiktok.com/@artotalent?_t... Apple Podcasts: https://podcasts.apple.com/us/podcast... Website: https://arto-talent.com Youtube: https://www.youtube.com/@artotalent Daniel Shearer Head of Automation at FUJIFILM Biotechnologies LinkedIn: https://www.linkedin.com/in/daniel-shearer-80574b36/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:24 $400M Multi-Modal Asset 01:38 Automation Challenges 06:59 Standardisation 11:18 Integration + Common Pitfalls Hosted on Acast. See acast.com/privacy for more information.

    17 min
  2. The Relentless Mindset Behind Scaling a Drug Manufacturing Company | Philippe Clavel

    HACE 6 DÍAS

    The Relentless Mindset Behind Scaling a Drug Manufacturing Company | Philippe Clavel

    Building a CDMO capable of taking therapies from early discovery to commercial supply requires more than scale. It requires scientific depth, operational discipline and a culture that embraces problems rather than avoids them. This week on Making It In Manufacturing, Harry Sloan sat down with Philippe Clavel, CEO of Curapath, bringing decades of experience across pharmaceutical manufacturing, leadership and CDMO strategy. In this episode, Philippe Clavel covers: • The evolution of CuraPath from a university spin-off focused on polymer science to a drug delivery CDMO serving biotech and large pharmaceutical companies (00:00) • Why deep scientific expertise in polymer science and lipid nanoparticles is essential for solving complex drug delivery challenges and improving manufacturing processes (02:29) • How CuraPath transitioned from early-stage discovery work to commercial manufacturing, growing from 0% commercial revenue to roughly 30% within five years (05:14) • The operational realities of scaling into GMP manufacturing, including building robust processes, documentation and training across the organisation (10:12) • Why successful CDMO partnerships are built on trust, technical questioning and understanding the deeper motivations behind a customer’s drug development programme (17:00) If you’re interested in the realities of scaling a specialist CDMO, building high-trust biotech partnerships and transforming scientific innovation into manufacturable therapies, this conversation offers valuable insight from someone leading that journey firsthand. Follow ARTO LinkedIn: / artotalent Spotify: https://open.spotify.com/show/0kEcRZO... Instagram: https://www.instagram.com/arto.talent... TikTok: https://www.tiktok.com/@artotalent?_t... Apple Podcasts: https://podcasts.apple.com/us/podcast... Website: https://arto-talent.com/ Youtube: @life_sciences Philippe Clavel LinkedIn: / philippe-clavel-cdmo-gxapis Harry Sloan / harry-sloan-605620154 Timestamps 00:00 Introduction 00:17 Overview of CuraPath and its drug delivery focus 02:29 What differentiates CuraPath as a CDMO 04:00 Balancing cost, scalability and complex modalities 05:14 Growth from discovery projects to commercial manufacturing 06:10 Expanding expertise from polymers to lipid nanoparticle technologies 07:41 Supporting customers across the full development journey 09:21 The significance of delivering a therapy reaching the market 10:12 Transitioning to GMP manufacturing and operational discipline 11:34 Challenges that come with scaling CDMO operations 13:27 Building a culture that embraces problems and deviations 15:27 Understanding customer motivations and building trust 18:24 Collaboration across supply chains within drug manufacturing 21:17 Maintaining company culture while scaling leadership 23:32 Encouraging challenge and empowerment within teams 27:13 Advice for business development professionals in CDMO 31:08 Future outlook for CuraPath and its pipeline 34:25 Personal motivation behind leading the company 39:02 Episode closing #MakingItInManufacturing #ARTOTalent #CDMO #PharmaceuticalManufacturing #DrugDelivery #Biotech #LifeSciences Hosted on Acast. See acast.com/privacy for more information.

    39 min
  3. How Pharma Actually Sets Global Standards (GAMP Explained)

    23 MAR

    How Pharma Actually Sets Global Standards (GAMP Explained)

    95% of our listeners aren't following, please check! What does it take to standardise an entire industry, and keep pace with AI, cloud, and digital transformation? This week on Making It in Manufacturing, we feature Thana Subramanian, GAMP Global Steering Committee Co-Chair, with over 32 years of experience in idustry, with 25 years as an ISPE member and 15 years as part of the GAMP CoP. In this episode, Thana covers: - The history and purpose of ISPE and its role in advancing pharmaceutical manufacturing - How GAMP evolved alongside regulatory bodies like the FDA and EMA - The benefits of ISPE membership, from networking to access to global best practices - The origins and evolution of GAMP, from early guidance to modern AI-driven systems - The objectives and key themes of the latest GAMP UK Conference, including AI, digital validation, and data integrity If you’re working in pharma, biotech, or advanced manufacturing, this episode gives you a clear lens into how global standards are shaped — and where the industry is heading next. Be sure to check out the full episode. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/?viewAsMember=true Spotify: https://open.spotify.com/show/0kEcRZO... Instagram: https://www.instagram.com/arto.talent... TikTok: https://www.tiktok.com/@artotalent?_t... Apple Podcasts: https://podcasts.apple.com/us/podcast... Website: https://arto-talent.com Youtube: https://www.youtube.com/@artotalent Thana Subramanian GAMP Global Steering Committee Co-Chair LinkedIn: https://www.linkedin.com/in/thanasubramanian/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:27 ISPE History 02:33 GAMP New Good Practice Guide (GxP Process Control Systems) Third Edition 07:32 Benefits of ISPE and GAMP Hosted on Acast. See acast.com/privacy for more information.

    15 min
  4. How Xellia Is Reshaping Europe’s Antibiotics Market | CEO Michael Kocher

    26 FEB

    How Xellia Is Reshaping Europe’s Antibiotics Market | CEO Michael Kocher

    What does it take to turn around a global antibiotic manufacturer and redefine its future in one of the toughest market environments in Europe? This week, in another episode of the Making It in Manufacturing Spotlight Series, hosted by @Thomas McMann we sit down with @Michael Kocher, CEO of @Xellia, who brings over two decades of leadership experience across global pharma and large-scale operations. With a career spanning senior roles in big-pharma and now leading a globally influential API manufacturer, Michael shares a remarkably honest look at the realities, decisions, and opportunities shaping Xellia today. In this episode, Michael covers: - Surprises from his first two years as CEO, including the talent, mindset, and culture he found inside Xellia. - His early strategic focuses, stabilising finances, divesting business operations, and rebuilding a sustainable foundation. - Xellia’s key differentiators, its portfolio of anti-infectives, their role in fighting severe infections and AMR. - The decision to close its Copenhagen manufacturing site over 8-10 years, why the long-term shift was necessary and how it impacts future manufacturing. - European policy and market pressures, reimbursement challenges, OPEX subsidies, and why reshoring isn’t realistic. - Future priorities, financial strengthening, product transfers, market-share growth, and new product launches. - Biggest opportunities ahead, expanding the fermentation-based API portfolio and doubling down on critical medicines. Full Podcast Be sure to check out this episode to hear Michael’s candid perspective on leadership, manufacturing, European policy, and what it truly takes to win in today’s API landscape. Follow ARTO: LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ YouTube: https://www.youtube.com/@life_sciences Michael Kocher CEO at Xellia Pharmaceuticals LinkedIn: https://www.linkedin.com/in/michael-kocher-191863a/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Hosted on Acast. See acast.com/privacy for more information.

    12 min
  5. The Untold Reality of Scaling Global Pharma Manufacturing - Xellia Pharmaceuticals

    18 FEB

    The Untold Reality of Scaling Global Pharma Manufacturing - Xellia Pharmaceuticals

    97% of our viewers don't realise they aren't subscribed, please double check, thank you! What does it really take to scale pharmaceutical manufacturing globally, without losing sight of patients? In this standout episode of Making It in Manufacturing, we sit down with Preben Haaning, Board Member at Xellia Pharmaceuticals, and a global pharmaceutical executive with 25+ years of experience spanning sales, finance, site leadership, and board-level strategy. Preben shares lessons from an extraordinary career: including his pivotal years at Novo Nordisk, where he helped scale global manufacturing networks and supported the early foundations of today’s GLP-1 supply chain. In this episode, Preben covers: How Xellia Pharmaceuticals is scaling critical anti-infectives while maintaining reliable global supply His unconventional journey from the military into life sciences leadership, and what it taught him about resilience and decision-making Real-world examples of project success and failure, including moments where patient access was directly at risk What it’s like operating as a global pharmaceutical executive, managing multi-site, multi-culture manufacturing networks Inside Novo Nordisk’s US expansion, including the launch of its first US-produced drug and early GLP-1 manufacturing challenges If you’re working in pharmaceutical manufacturing, engineering, operations, or leadership, this is an episode packed with hard-won insight from the front lines. 👉 Be sure to check out the full episode and subscribe for more conversations with the leaders shaping life-sciences manufacturing. Follow ARTO LinkedIn:   / artotalent   Spotify: https://open.spotify.com/show/0kEcRZO... Instagram: https://www.instagram.com/arto.talent... TikTok: https://www.tiktok.com/@artotalent?_t... Apple Podcasts: https://podcasts.apple.com/us/podcast... Website: https://arto-talent.com Youtube:    / @life_sciences   Preben Haaning Board Member at Xellia Pharmaceuticals LinkedIn:   / preben-haaning-18a6193   Thomas McMann Director - Contracts Division LinkedIn:   / thomas-mcmann-05540a10b   Timestamps: 02:03 Xellia Pharmaceuticals 11:07 From the Military to Life Sciences 19:11 Project Success and Failure 28:51 Global Pharmaceutical Executive 46:41 Novo Nordisk Expansion of US Supply Hosted on Acast. See acast.com/privacy for more information.

    1 h 2 min
  6. Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

    12 FEB

    Inside Mabion’s Growth Strategy | CEO Gregor Kawaletz on Biosimilars & Biologics

    What does it take to step into a publicly listed CDMO and immediately reposition it for growth in a shifting global market? At Mabion, it starts with people, scientific excellence and a clear commercial vision. This week on Making It In Manufacturing, Thomas McMann sat down with Gregor Kawaletz, CEO of Mabion, bringing over 20 years of experience in the CDMO space spanning leadership roles across NextPharma, Catalent and Recipharm. Now in the first month as CEO, Gregor shares why this move was about broader impact and how the organisation will be steered into its next phase. In this episode, Gregor covers: • The first month as CEO at @Mabion and why “every company is about people” • The transition from Chief Commercial Officer roles into a CEO position with responsibility for the full organisation • Growth priorities, pipeline confidence and an upcoming adjusted business model • The €500,000 innovation initiative and awarding @WPD for novel antibody drug conjugate programmes in oncology • Regulatory shifts in the biosimilar space and how reduced requirements are expanding patient access The conversation also explores operating in a more multipolar global environment and why CDMOs must move beyond traditional fee-for-service models toward deeper collaboration and network thinking. For professionals in biologics, biosimilars or CDMO partnerships, this episode offers strategic insight shaped by experience across NextPharma, Catalent, Recipharm and now at Mabion. Check out this episode to hear how scientific depth, commercial leadership and organisational alignment can reposition a CDMO for long-term success. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ Youtube: https://www.youtube.com/@life_sciences Gregor Kawaletz - CEO at Mabion LinkedIn: https://www.linkedin.com/in/gregor-kawaletz-276a4830/ Thomas McMann - Director At ARTO LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:00 First month as CEO at Mabion 02:19 Two decades in the CDMO space including NextPharma, Catalent and Recipharm 02:42 Moving from CCO to CEO 05:10 Growth strategy and business model evolution 06:57 €500k innovation award and WPD 09:41 Biosimilars regulation and market access 11:04 Navigating a multipolar global supply landscape 12:47 Expanding Mabion’s future offering #MakingItInManufacturing #ARTOTalent #CDMO #Biologics #Biosimilars #LifeSciences #ManufacturingLeadership Hosted on Acast. See acast.com/privacy for more information.

    14 min
  7. Building Trust in Pharma and Biotech Manufacturing Partnerships | Sharp Services

    29 ENE

    Building Trust in Pharma and Biotech Manufacturing Partnerships | Sharp Services

    What does it really take to build trust in pharmaceutical and biotech partnerships when timelines are tight, expectations are high, and the market never stands still? This week on Making It In Manufacturing, Tom McMann sat down with Alexander Schäfer, Business Development Manager, to unpack what strong execution, honest communication, and long-term thinking look like inside global contract packaging services. In this episode, Alexander shares insights from his work across European operations in pharmaceutical and biotech packaging, supporting everyone from early-stage virtual biotechs to established blue-chip pharma organisations. Speaking from the floor of CPHI, one of the industry’s most important global events, he breaks down how expectations shift across company sizes and why trust is earned through delivery, not promises. Throughout the conversation, Alexander references the realities of operating at scale within global packaging services, the importance of listening to market demand, and how investment decisions are shaped by customer needs and long-term industry trends. In this episode, Alexander Schäfer covers: • How servicing small biotechs versus large pharma companies requires different approaches to expectations and support (01:28) • Why trust in business development is built through execution, consistency, and reputation over time (03:12) • The importance of open communication and solution-led thinking when projects face challenges (04:24) • What skills matter most in business development, including listening, asking the right questions, and understanding customer pain points (06:29) • How major investments into packaging capacity, injectables, and device assembly are shaping the future of the industry (07:21) This conversation was recorded during CPHI, where industry leaders come together to discuss innovation, investment, and the future of pharmaceutical manufacturing. It offers a grounded look at how business development works behind the scenes in a highly regulated, fast-moving environment. If you are working in pharma, biotech, manufacturing, or commercial leadership, this episode offers practical insight into how long-term partnerships are built and sustained. Check out the full episode now. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent Spotify: https://open.spotify.com/show/0kEcRZOiJChOoN1KF2n1ng Instagram: https://www.instagram.com/arto.talent?igsh=MWdhbWl5N204a253NQ%3D%3D&utm_source=qr TikTok: https://www.tiktok.com/@artotalent?_t=ZG-8tHbGACAZaj&_r=1 Apple Podcasts: https://podcasts.apple.com/us/podcast/leading-beyond-the-lab/id1783115575 Website: https://arto-talent.com/ YouTube: https://www.youtube.com/@life_sciences Alexander Schäfer LinkedIn: https://www.linkedin.com/in/alexander-sch%C3%A4fer-4515a433/ Tom McMann LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:00 Introduction and context from CPHI 00:54 Overview of European operations and contract packaging services 01:28 Servicing biotech versus pharma clients 03:12 Building trust through execution and reputation 04:24 Managing challenges with open communication and solutions 06:29 Essential skills for business development professionals 07:21 Investment in injectables, devices, and future capacity 10:25 Closing reflections #MakingItInManufacturing #ARTOTalent #PharmaManufacturing #Biotech #BusinessDevelopment #CPHI #ContractPackaging Hosted on Acast. See acast.com/privacy for more information.

    10 min
  8. What Makes a CDMO Investable? Ankit Gupta on Building Instapill for Long-Term Growth

    16 ENE

    What Makes a CDMO Investable? Ankit Gupta on Building Instapill for Long-Term Growth

    The CDMO Changing the Game in Drug Delivery This week, in another episode of the Making it in Manufacturing Spotlight Series, we sit down with Ankit Gupta, CEO of Instapill, a company redefining oral drug delivery through freeze-dried, fast-dissolving tablets. With over 15 years of experience spanning investment banking, M&A, and leadership roles in pharmaceutical manufacturing, Ankit brings a sharp perspective on scaling, innovation, and sustainable differentiation. In this episode, Ankit covers: Instapill’s unique FDA-approved non-gelatin ODT technology and why it’s transforming patient outcomes in paediatrics and geriatrics.Scaling up manufacturing capacity in India and future expansion plans into the US, and how automation will maintain quality at scale.How digital transformation and AI are shaping pharmaceutical manufacturing, from paperless R&D to data-driven precision in production.What makes a CDMO attractive to investors, and how sustainable differentiation trumps trend-driven momentum.Lessons from M&A and investment banking, and how they inform his approach as a CEO leading growth in a competitive CDMO landscape. Be sure to check out this episode to hear how Instapill is not only innovating formulation, but reimagining the future of pharma manufacturing. To listen to (or watch) the full episode, search "Making it in Manufacturing Instapill" on your preferred streaming platform. Or, click on the first link in the comments below. Follow ARTO LinkedIn: https://www.linkedin.com/company/artotalent/ Spotify: https://open.spotify.com/show/0kEcRZO... Instagram: https://www.instagram.com/arto.talent... TikTok: https://www.tiktok.com/@artotalent?_t... Apple Podcasts: https://podcasts.apple.com/us/podcast... Website: https://arto-talent.com Youtube: https://www.youtube.com/@life_sciences Ankit Gupta CEO at Instapill LinkedIn: https://www.linkedin.com/in/reachankit/ Thomas McMann Director - Contracts Division LinkedIn: https://www.linkedin.com/in/thomas-mcmann-05540a10b/ Timestamps: 00:11 Stand Out FDA Approval & Speed to Market 08:00 Global Growth and Operations 10:55 Insights & Leadership Takeaways Hosted on Acast. See acast.com/privacy for more information.

    14 min
Ver todo (20)

Acerca de

97% of our listeners don't realise they aren't followed, please double check, thank you! Hosted by Thomas McMann, Making It In Manufacturing is ARTO's new in-person podcast series, spotlighting the leaders shaping the future of manufacturing, engineering and CDMOs in Life Sciences. Each episode dives into the careers, decisions, and defining moments of industry mainstays - revealing the stories and insights behind real-world impact within the life science manufacturing and CDMO space. If you're a leader in the space - or aspiring to be - this podcast is a must watch. The series is available on YouTube, Spotify, Apple Podcasts and all major platforms. Hosted on Acast. See acast.com/privacy for more information.

Información

  • Creador
    ARTO Talent
  • Años de actividad
    2025 - 2026
  • Episodios
    20
  • Clasificación
    Apto
  • Copyright
    © ARTO Talent
  • Mostrar sitio web
    Making it in Manufacturing

También te podría interesar